Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
AUTOR(ES)
Carvalho, Clarissa Luiza Dalla Bernardina, Ortigosa, Luciena Cegatto Martins
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2014-01
RESUMO
The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
Documentos Relacionados
- Type 2 segmental glomangioma - Case report
- Piloleiomyoma with segmental distribution - Case report
- Honeycomb Lung and Chronic Rheumatoid Arthritis: A Case Report
- Coexistent rheumatoid arthritis and tophaceous gout: a case report.
- Inflammatory segmental vitiligo during oral isotretinoin use: a casual association?,